1. Home
  2. SAFT vs EVO Comparison

SAFT vs EVO Comparison

Compare SAFT & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Safety Insurance Group Inc.

SAFT

Safety Insurance Group Inc.

HOLD

Current Price

$74.12

Market Cap

1.0B

Sector

Finance

ML Signal

HOLD

Logo Evotec SE

EVO

Evotec SE

HOLD

Current Price

$3.12

Market Cap

1.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SAFT
EVO
Founded
1979
1993
Country
United States
Germany
Employees
N/A
N/A
Industry
Property-Casualty Insurers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.0B
1.1B
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
SAFT
EVO
Price
$74.12
$3.12
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$7.00
AVG Volume (30 Days)
94.9K
90.8K
Earning Date
11-03-2025
11-05-2025
Dividend Yield
4.95%
N/A
EPS Growth
15.78
N/A
EPS
5.87
N/A
Revenue
$1,231,116,000.00
$887,396,457.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$8.80
P/E Ratio
$12.75
N/A
Revenue Growth
12.77
N/A
52 Week Low
$67.04
$2.84
52 Week High
$89.33
$5.10

Technical Indicators

Market Signals
Indicator
SAFT
EVO
Relative Strength Index (RSI) 47.92 41.59
Support Level $74.63 $3.08
Resistance Level $77.37 $3.24
Average True Range (ATR) 1.43 0.09
MACD -0.38 0.04
Stochastic Oscillator 10.79 48.91

Price Performance

Historical Comparison
SAFT
EVO

About SAFT Safety Insurance Group Inc.

Safety Insurance Group Inc is a provider of private passenger automobile, commercial automobile, and homeowners insurance in Massachusetts. The company also offers property and casualty insurance products, including commercial automobiles, homeowners, dwelling fire, umbrella, and business owner policies. It operates in the business segment of Property and casualty insurance operations.

About EVO Evotec SE

Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.

Share on Social Networks: